Andrew Huberman· PhD
Now we do it with gene therapy in the eye and other places. So in the IES, it's single injection, the genes go into the retina and we can turn it on, with a drug called doxycycline.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Now we do it with gene therapy in the eye and other places. So in the IES, it's single injection, the genes go into the retina and we can turn it on, with a drug called doxycycline.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.